Remove 2019 Remove Immunization Remove Insurance
article thumbnail

Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025

Pharmacy Times

3 Her program focuses on an appointment-based model and has a cash-based payment model, although they are able to bill some insurances for the visit. 4 Novak added that these services align well with appointment-based models and can be layered with immunizations, chronic disease monitoring, and medication therapy management.

article thumbnail

Is prednisone good for migraines?

The Checkup by Singlecare

They’re prescription drugs that work by reducing swelling and symptoms caused by immune system reactions. A 2019 article in Evidence-Based Practice suggests this, too. Prednisone (and dexamethasone ) are corticosteroids that treat conditions such as allergies, inflammation, asthma, and much more.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Pharmacy Times

1,2 Tafamidis in the Treatment of ATTR-CM Initially approved in 2019 3 , tafamidis (Vyndamax; Pfizer) is a selective transthyretin (TTR) kinetic stabilizer that binds to thyroxine-binding sites on TTR tetramers, which prevents dissociation into monomers, or the breakdown into amyloid deposits that damage the heart in ATTR-CM. May 6, 2019.

article thumbnail

Managing Tardive Dyskinesia With VMAT2 Inhibitors in Clinical Practice

Pharmacy Times

Treatment selection is influenced by insurance, cost, and patient-specific factors due to the lack of direct RCT comparisons. 7 Based on a lack of head-to-head randomized clinical trials (RCTs), selection of the most appropriate VMAT2 inhibitor is routinely related to insurance approval, affordability, and patient-specific characteristics.

article thumbnail

Mifepristone Reduces HbA1c in Patients With T2D, Hypercortisolism | ADA 2025

Drug Topics

0 Copay Program Effectively Improved Glycemic Control | ADA 2025 Brian Nowosielski June 24th 2025 Article Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

article thumbnail

Study Reveals Alarming Gaps in HER2 Therapy Access for Patients With Breast Cancer

Pharmacy Times

Utilization of HER2 therapies is positively associated with private insurance, academic facility treatment, and recent diagnosis years. Disparities in HER2 therapy access are linked to rural treatment, Black race, Medicare insurance, and older age. 3 Among the patients, approximately 75.8% in 2013 to 80.9% in 2013 to 80.9%

article thumbnail

GLP-1 Use Increased Significantly Among Pediatric Patients With T2D in Past 5 Years | ADA 2025

Drug Topics

Glucagon-like peptide-1 (GLP-1) receptor agonist use rose significantly among pediatric patients with type 2 diabetes from 2019 to 2024, according to recent data presented at the American Diabetes Association’s 85th Scientific Sessions, which were held June 20-23 in Chicago, Illinois. in 2019, that number fell to 7.8% References 1.